Inj. fe derisomaltose 10 mg
Products billed under this code include Monoferric.
Payment limit per 10 MG, by effective quarter, 3Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Monoferric.
Payment limit per 10 MG, by effective quarter, 3Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Monoferric | Pharmacosmos Therapeutics Inc. | 73594-9310-01 | 100 | $2,187.70 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $21.877 | +$0.80 | 10 MG | Inj. fe derisomaltose 10 mg | v1, posted September 17, 2026 |
| 3Q26 | $21.077 | −$0.853 | 10 MG | Inj. fe derisomaltose 10 mg | v1, posted September 15, 2026 |
| 2Q26 | $21.93 | −$0.899 | 10 MG | Inj. fe derisomaltose 10 mg | v1, posted September 15, 2026 |
| 1Q26 | $22.829 | +$0.811 | 10 MG | Inj. fe derisomaltose 10 mg | v1, posted September 15, 2026 |
| 4Q25 | $22.018 | +$3.067 | 10 MG | Inj. fe derisomaltose 10 mg | v1, posted September 8, 2026 |
| 3Q25 | $18.951 | −$1.875 | 10 MG | Inj. fe derisomaltose 10 mg | v1, posted March 10, 2026 |
| 2Q25 | $20.826 | +$0.052 | 10 MG | Inj. fe derisomaltose 10 mg | v1, posted March 10, 2026 |
| 1Q25 | $20.774 | −$0.278 | 10 MG | Inj. fe derisomaltose 10 mg | v1, posted December 19, 2025 |
| 4Q24 | $21.052 | +$0.405 | 10 MG | Inj. fe derisomaltose 10 mg | v1, posted June 11, 2025 |
| 3Q24 | $20.647 | +$0.711 | 10 MG | Inj. fe derisomaltose 10 mg | v1, posted June 11, 2025 |
| 2Q24 | $19.936 | +$1.073 | 10 MG | Inj. fe derisomaltose 10 mg | v1, posted March 11, 2025 |
| 1Q24 | $18.863 | −$1.196 | 10 MG | Inj. fe derisomaltose 10 mg | v1, posted December 19, 2024 |
| 4Q23 | $20.059 | −$0.554 | 10 MG | Inj. fe derisomaltose 10 mg | v1, posted October 10, 2024 |
| 3Q23 | $20.613 | −$1.085 | 10 MG | Inj. fe derisomaltose 10 mg | v1, posted June 5, 2024 |
| 2Q23 | $21.698 | −$1.015 | 10 MG | Inj. fe derisomaltose 10 mg | v1, posted February 23, 2024 |
| 1Q23 | $22.713 | −$0.253 | 10 MG | Inj. fe derisomaltose 10 mg | v1, posted December 6, 2023 |
| 4Q22 | $22.966 | −$0.064 | 10 MG | Inj. fe derisomaltose 10 mg | v1, posted June 22, 2023 |
| 3Q22 | $23.03 | −$1.187 | 10 MG | Inj. fe derisomaltose 10 mg | v1, posted June 9, 2023 |
| 2Q22 | $24.217 | −$0.181 | 10 MG | Inj. fe derisomaltose 10 mg | v1, posted December 14, 2022 |
| 1Q22 | $24.398 | −$0.47 | 10 MG | Inj. fe derisomaltose 10 mg | v1, posted June 8, 2022 |
| 4Q21 | $24.868 | −$0.947 | 10 MG | Inj. fe derisomaltose 10 mg | v1, posted June 2, 2022 |
| 3Q21 | $25.815 | – | 10 MG | Inj. fe derisomaltose 10 mg | v1, posted June 2, 2022 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.